Is It Time to Put a Moratorium on New Infant Formulas that Are Not Adequately Investigated?
Infant formula sales in the US are a competitive and profitable marketplace environment. FDA restrictions on such new formula releases are designed to ensure that there is minimal evidence of risk, but often the evidence for benefit is not established. Some of these products may confuse families relative to the value of breastfeeding or to the value of spending money on more expensive formulas than are medically needed. In other cases, they lead to multiple formula switches over relatively minor symptoms that would best be managed through parental education. They may also pose risks for populations including late preterm infants or infants with other risk factors for poor growth.